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Abstract  
 
Proton therapy for treating cancer patients has been evolved to become a highly 
desired choice of radiation therapy due to the physical characteristic of protons. 
Currently, the biologic effectiveness of protons relative to photons is considered to be a 
constant ratio of 1.1. However, experiments show that the RBE is higher in different 
portions in proton ranges. Since the usage of a constant RBE is justified based on 
experiments conducted using older methods of dose delivery, the re-evaluation of using a 
constant RBE and proposing models for determining RBE values is necessary now that 
recent experimental results, using new actively scanned beam delivery method, are 
available and suggest deviations from conventional data. To suggest a method for 
calculating RBE values, an experiment by Guan et al. is chosen to derive biologic 
response results with respect to proton beams. A widely used phenomenological RBE 
model by Wilkens and Oeflke is chosen for comparison purposes. The proposed RBE 
model is based on Wilkens and Oeflke model with revisions on tissue parameters 
behavior vs. LET based on Guan et al results. Three RBE models including the constant 
RBE, Wilkens' model and the suggested model based on Guan’s experiment are 
compared for three brain cancer patient cases. The comparisons are demonstrated using 
cumulative RBE weighted dose volume histograms. The sensitivity of models to tissue 
parameter changes are also analyzed. The suggested model shows escalated variable RBE 
weighted dose compared to constant RBE weighted dose, and it is sensitive to RBE 
model parameters in all three patient studies. 
 vi 
 
Table of Contents 
 
Abstract ............................................................................................................................... v 
Table of Contents ............................................................................................................... vi 
List of Figures .................................................................................................................. viii 
List of Tables .................................................................................................................... xii 
Introduction ......................................................................................................................... 1 
1.1 Background and Motivation ...................................................................................... 1 
1.2 Problem Statement .................................................................................................... 6 
1.2.1 Comparison of Relative Biological Effectiveness for Three RBE Models ........ 6 
1.3 Contributions ............................................................................................................. 7 
1.5 Organization .............................................................................................................. 8 
Literature Review................................................................................................................ 9 
2.1 Radiation Therapy ..................................................................................................... 9 
2.2 Proton Therapy ........................................................................................................ 11 
2.3 Relative Biological Effectiveness ........................................................................... 13 
Methods............................................................................................................................. 19 
3.1 Introduction ............................................................................................................. 20 
3.2 Preliminaries of Relative Biological Effectiveness ................................................. 25 
3.2.1 RBE Characteristics and Definitions ................................................................ 26 
 vii 
 
3.2.2 Study Steps ....................................................................................................... 34 
3.3 RBE Models ............................................................................................................ 35 
3.3.1 Choice of RBE Studies ..................................................................................... 35 
3.3.2 Wilkens’ Method for Calculating the Variable RBE........................................ 36 
3.3.3 Guan et al. Experiment ..................................................................................... 40 
Results ............................................................................................................................... 52 
4.1 Calculated RBE Results .......................................................................................... 53 
4.2 Sensitivity Analysis ................................................................................................. 55 
4.2.1 Sensitivity to αx/βx Fluctuations ....................................................................... 55 
4.2.2 Sensitivity of vRBE-Guan to Fit Parameters .................................................... 61 
Conclusions ....................................................................................................................... 68 
Future Work ...................................................................................................................... 70 
References ......................................................................................................................... 72 
 
  
 viii 
 
List of Figures 
 
Figure 1  Depth-dose characteristics of proton and photon beams (Skinner and Komaki). 4 
Figure 2  Illustration of the main radiotherapy planning volumes. (Burnet et al.) ........... 27 
Figure 3 Planning CT showing the visibility of GTV, margin for microscopic spread of 
the tumor (CTV), and marginal PTV (Burnet et al.). ........................................................ 28 
Figure 4 illustrates the structure definitions and their schematic locations inside treatment 
area. ................................................................................................................................... 29 
Figure 5  Cumulative Dose Volume Histogram of a radiation for five different structures, 
representing the RBE*Dose   with respect to fraction of volume. .................................... 33 
Figure 6 Experimental results for the LQ parameters for survival of V79 Chinese hamster 
(J. J. Wilkens and U. Oelfke). ........................................................................................... 39 
Figure 7 Comparison of passive scattering beams and actively scanned beams energy 
spectra (Guan et al.). ......................................................................................................... 41 
Figure 8  The device (Jig) and a schematic illustration of how the jig reduces the energy 
in a stepwise manner (Guan et al.) .................................................................................... 42 
Figure 9  RBE vs. LET plot of the Guan et al experiment results (Guan et al.). Blue and 
red lines show two similar types of cell lines’ results for comparison. ............................ 43 
Figure 10  Quadratic fit for the relationship between Alpha tissue parameters and LET. 46 
Figure 11  Quadratic fitted relationship to model the relationship between Beta values 
and LET ............................................................................................................................ 46 
Figure 12  Linear fit of Alpha parameter vs. LET for lower LET values, and quadratic 
relationship considered for higher LET values ................................................................. 47 
 ix 
 
Figure 13 Linear fit of Beta parameter vs. LET for lower LET values, and quadratic 
relationship considered for higher LET values ................................................................. 47 
Figure 14 Fitted Guan et al. experiment data for α and LET, to piecewise linear and 
quadratic functions ............................................................................................................ 50 
Figure 15 Fitted Guan et al. experiment data for β and LET, to piecewise linear and 
quadratic functions ............................................................................................................ 50 
Figure 16  Cumulative RBE weighted dose volume histograms of three RBE model for 
patient 1. The dashed lines are used to show the vRBE-Wilkens, the dotted lines pertain 
to constant RBE, and the solid lines are used to demonstrate vRBE-Guan. ..................... 53 
Figure 17  Cumulative RBE weighted dose volume histograms of three RBE model for 
patient 2. The dashed lines are used to show the vRBE-Wilkens, the dotted lines pertain 
to constant RBE, and the solid lines are used to demonstrate vRBE-Guan. ..................... 54 
Figure 18  Cumulative RBE weighted dose volume histograms of three RBE model for 
patient 3. The dashed lines are used to show the vRBE-Wilkens, the dotted lines pertain 
to constant RBE, and the solid lines are used to demonstrate vRBE-Guan. ..................... 54 
Figure 19  Sensitivity of vRBE-Guan to αx/βx ± 0.3 fluctuations – Patient 1. Dotted line 
demonstrates the upper 0.3, and dashed lines show the lower 0.3 limits. ........................ 56 
Figure 20  Sensitivity of vRBE-Wilkens’ to αx/βx  ± 0.3 fluctuations– Patient 1 .Dashed 
line demonstrates the upper 0.3, and dotted lines show the lower 0.3 limits.................... 56 
Figure 21  Sensitivity of vRBE-Guan to αx/βx ± 0.3 fluctuations patient 2. Dotted line 
demonstrates the upper 0.3, and dashed lines show the lower 0.3 limits. ........................ 58 
Figure 22   Sensitivity of vRBE-Wilkens to αx/βx ± 0.3 fluctuations patient 2. Dotted line 
demonstrates the upper 0.3, and dashed lines show the lower 0.3 limits. ........................ 58 
 x 
 
Figure 23   Sensitivity of vRBE-Guan to αx/βx ± 0.3 fluctuations vRBE-Guan patient 3.   
Dotted lines demonstrates the upper 0.3, and dashed lines show the lower 0.3 limits. .... 59 
Figure 24   Sensitivity of vRBE-Wilkens’ to αx/βx ± 0.3 fluctuations patient 3. Dotted 
line demonstrates the upper 0.3, and dashed lines show the lower 0.3 limits .................. 59 
Figure 25  Calculated vRBE-Guan values for αx/βx ± 30%, 20%, and 10% for patient 1. 60 
Figure 26  Calculated vRBE-Wilkens values for αx/βx ± 30%, 20%, and 10% for patient 1.
........................................................................................................................................... 61 
Figure 27  Sensitivity of vRBE-Guan to α ± 0.3 Vs. LET fit parameter 0.3 changes – 
Patient 1. Dotted lines correspond to increased alpha parameters, dashed lines show the 
effect of decreasing the alpha fit parameters, and the solid line shows the originally 
calculated RBE.................................................................................................................. 62 
Figure 28  Sensitivity of vRBE-Guan to α ± 0.3 Vs. LET fit parameter 0.3 changes – 
Patient 1. Dotted lines correspond to increased alpha parameters, dashed lines show the 
effect of decreasing the alpha fit parameters, and the solid line shows the originally 
calculated RBE.................................................................................................................. 63 
Figure 29  Sensitivity of vRBE-Guan to α ± 0.3 Vs. LET fit parameter 0.3 changes – 
Patient 3. Dotted lines correspond to increased alpha parameters, dashed lines show the 
effect of decreasing the alpha fit parameters, and the solid line shows the originally 
calculated RBE.................................................................................................................. 63 
Figure 30  Sensitivity of vRBE-Guan to α ± 0.3, 0.2, and 0.1 Vs. LET fit parameter 0.3 
changes – Patient 1. Dotted lines correspond to increased alpha parameters, dashed lines 
show the effect of decreasing the alpha fit parameters, and the solid line shows the 
originally calculated RBE values. ..................................................................................... 64 
 xi 
 
Figure 31  Sensitivity of vRBE-Guan RBE model to β ± 0.3 Vs. LET fit parameter with 
30% changes for patient 1 ................................................................................................. 65 
Figure 32 Sensitivity of vRBE-Guan RBE model to β ± 0.3 Vs. LET fit parameter 
changes for patient 2 ......................................................................................................... 66 
Figure 33  Sensitivity of vRBE-Guan RBE model to β Vs. LET fit parameter changes for 
patient 3 ............................................................................................................................. 66 
Figure 34  Sensitivity of vRBE-Guan to β ± 0.3, 0.2, and 0.1 Vs. LET fit parameter 0.3 
changes – Patient 1. Dotted lines correspond to increased beta parameters, dashed lines 
show the effect of decreasing the beta fit parameters, and the solid line shows the 
originally calculated RBE. ................................................................................................ 67 
 
 
 
 
 
  
 xii 
 
 
List of Tables  
 
Table 1  Alpha, Beta, and LET averages as the ultimate result of Guan et al experiment 
(Guan et al.). ..................................................................................................................... 44 
Table 2   Tissue parameters for photons and average dose – volume statistics for target 
volume and organs at risk  (Frese et al.) ........................................................................... 48 
 
 1 
 
 
Chapter 1 
Introduction 
1.1 Background and Motivation 
According to a report by Hannah Nichols published in MNT website 
(medicalnewstoday.com), cancer was the second cause of deaths after heart disease in 
United States in 2012, with 584,881 deaths (Nichols). There were 14.1 million new 
cancer cases reported around the world in 2012 and it was estimated to grow to 24 
million cases by 2015 (International). Also there were 8.2 million deaths, 32.6 million 
people around the world living with cancer (GLOBOCAN). Considering present 
statistics, cancer disease is taking lives of a great number of people worldwide and leaves 
so many others at the risk of death. In addition to be deadly, the disease has economic 
impacts on the society worldwide. To more elaborate on the expenses cancer imposes, 
two viewpoints are presented here. First, the high costs of cancer treatment are 
considered. According to IMS institute, global spending on cancer treatment drugs has 
passed 100 billion dollars threshold in 2014 (Constantino). New cancer drugs are 
introduced every year and the amount spent on cancer drugs are increasing at the same 
time. That means more funds are being spent on the disease. The costs are putting 
individuals with cancer, and the governments with public funds allocated for cancer 
patients in a problematic situation. UK government has recently cut off a part of cancer 
drug funds as it is no longer able to afford it (Ward). On the other hand, as cancer causes 
premature death and disability, an economic cost other than direct medical costs of cancer 
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exists. A report of a research done jointly by American Cancer Society and 
LIVESTRONG on global economic impact of cancer indicates that an 895 billion dollar 
in total cost was imposed by premature death and disability caused by cancer in 2008. 
This accounts for 1.5 percent of gross domestic product worldwide. This is of more 
importance when the findings show that cancer is growing to become the first cause of 
death instead of heart disease and stroke (American cancer society). According to the 
formerly mentioned points, cancer has had to be taken seriously from the beginning and a 
significant amount of time and resources is devoted to research on the disease and its 
possible treatments. As a solution to a problem begins with understanding the problem 
and its characteristics, cancer has been under investigation. Below is a brief description 
on cancer.  
Cancer is a disease in which cells in any organ start to divide abnormally and 
uncontrollably leading to a whole body malfunction and death if not cured. Different 
types of cancer treatments have been found trough time, including Surgery, 
Chemotherapy, Radiation therapy, Immunotherapy, Targeted therapy, Hormone Therapy, 
Stem Cell Transplant, and Precision Medicine. The methods available for curing cancer, 
however, depend on the type of cancer (NIH).  
One of the cancer treatments is radiation therapy. The method was introduced in 
1903, five years after radium was discovered by Curie. Over the recent century radiation 
therapy has come a long way from being conceptualized to being implemented widely on 
many cancer patients in cancer treatment institutions (Brady et al.). Radium was used to 
emit Gamma ray at first, giving its place to Cobalt 60. Generally Gamma rays and X rays 
were often used before the use of heavy ions in radiotherapy was introduced. Cancer 
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radiotherapy treatment approach is uncertain in nature and always has been used despite 
the risks and uncertainties. Earlier methods for radiotherapy of the tumor cells however, 
had more built-in errors and risks as they were not very precise in defining the target 
volume and in optimization of the dose function.  Later on, the use of heavier ions was 
taken into consideration and implementation. The rationale for using proton or other 
heavy ions mostly was the characteristics of its dose distribution and “Bragg peak”. 
Heavy ions provide with a homogenous field in the target. Such ability is known as 
“spread-out-Bragg peak” which enables the maximum effectivity to include the whole 
tumor while sparing the normal tissue around it, is the outcome of the spread out Bragg 
peak. Keeping the healthy tissue around the tumor is important due to the probability of 
second hand cancers caused by irradiation of normal cells during radiotherapy. 
Furthermore, the dose distribution characteristics make the treatment process more 
effective. Proton beams are known to be the most practical of all heavy particles 
potentially used in radiation therapy.  
To create a homogenous field within the target, the intensity of the beams is 
modulated. Lomax has studied different types of intensity modulation methods for proton 
therapy to reach the conclusion that only the 3D localization of dose by individual narrow 
beam creates a Bragg peak in three dimensions to fully cover PTV (Planning Target 
Volume)(Lomax). Similar methods are also introduced by (Brahme, Källman and Lind) 
and (Carlsson, Andreo and Brahme). Such methods have made the treatment plans more 
precise than before, however, the need to further optimize the plans is yet to be met. The 
reason for such need is expressed in next paragraph; but in addition to the optimization of 
the plan discussion, the path to more precise and safer treatment plans is considered to 
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pass through the calculation of the “Relative Biological Effectiveness” (RBE) 
simultaneous to optimizing the treatment plan. That means considering the nearest to 
actual values for RBE when optimizing the dose. Such matter is discussed further in the 
problem statement section of this chapter. But a brief explanation of the motivation on 
the topic is given below.  
 
 
Figure 1  Depth-dose characteristics of proton and photon beams (Skinner and Komaki). 
 
There are many uncertainties in regard to proton therapy approach. One of these 
uncertainties is caused by the effectiveness of the beam in regard to the target tissue. The 
effectiveness of the proton beam depends on the dose, the rate at which the energy of the 
beam is delivered to the tumor mass, and the characteristics of the target tissue.  
The effectiveness of a beam is defined by a factor called “Biological Effect”. 
However, the value that is usually used to observe the effectiveness of a particular beam 
in regard to a tissue is the ratio of absorbed dose of a standard radiation to the beam that 
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is under study. The reference radiation is usually X-ray produced by Cobalt 60. The 
reason for this choice is the sufficient amount of available data because of previous high 
use of the radiation. Basically, the absorbed dose of the new radiation, is the absorbed 
dose that causes the same amount of biological effect that the reference radiation causes. 
The discussed ratio is called “Relative Biological Effectiveness”.  
The clinical implementation of proton therapy considers the RBE of proton beams 
as a constant value of 1.1. The value of 1.1 is derived from experimental results in in vivo 
and in vitro experiments and are justified to be used as a constant value which is also 
spatially invariant in the target volume. As the results from former experiments haven’t 
shown significant variation in the dose calculation quality when RBE is considered a 
variable compared to its constant assigned value, with regard to the large amount of 
uncertainties aligned to the RBE, the continual use of the constant 1.1 is still practiced in 
current clinical applications (Paganetti et al.). 
Despite the mentioned rationale for continual use of constant RBE, with further 
availability of clinical data for proton therapy results and target response to the treatment, 
considerable research has been done on relative biological effectiveness as a variable, and 
its dependence on dose, linear energy transfer, and tissue specific parameters. Also, the 
use of constant RBE was assumed to be the right choice only considering the older 
methods of dose delivery including passive scattering proton therapy and high dose per 
fraction (Guan et al.). Such methods also carried a large amount of uncertainty within the 
experimental data. With the emergence of newer system for delivering the proton beams 
to the target tissue the question of either using the same constant RBE or calculating the 
RBE as a variable rises again. As a result, further investigation on the nature and 
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characteristics of RBE seems a good start point for the journey. To begin, we can take a 
look at the former studies on variable RBE. 
Based on a report from (IARC), 7,054,446 cases of cancer were documented in 
the world with 8201 cases of death from cancer in 2012. Noting this and the formerly 
mentioned statistics, more study on cancer treatment methods seems extremely necessary 
to achieve better effectiveness. The severity of the issue is the motivation for optimizing 
the Proton therapy method used currently at the cancer treatment institutions.  
1.2 Problem Statement 
The purpose of this study is to investigate the impact of the recently developed 
RBE models on intensity modulated proton therapy (IMPT) treatment plans. A RBE 
model will be derived using the data from the experiment that is performed by Guan et al. 
(Guan et al.), and the RBE values from analogous RBE models will be compared. The 
difference between the variable and constant RBE weighted doses in retrospectively 
selected proton patient cases will be demonstrated. Finally, we will analyze the 
uncertainties in RBE model parameters in the same patient cases.  
1.2.1 Comparison of Relative Biological Effectiveness for Three RBE Models  
To evaluate the variable RBE and its uncertainties in IMPT treatment plans three 
brain tumor cases from patients who had received IMPT and clinical plans will be 
selected and exported. The LET and dose data from all beamlet to al voxels will be 
computed using Monte Carlo simulations. Subsequently, three RBE weighted doses will 
be compared along with the dose distribution and dose volume histograms. The three 
RBE weighted doses will be the constant RBE (cRBE), the variable RBE based on 
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Wilkens’ (J. J. Wilkens and U. Oelfke) which will be calculated from fitted LET, α and β 
data presented in that study (vRBE-Wilkens), and the third RBE will be a RBE based on 
Guan’s (Guan et al.), and presents a formulation for calculating RBE as a function of 
dose, LET and target tissue parameters (vRBE-Guan).  
1.3 Contributions 
This dissertation contributes to the literature by further investigating in the 
question of whether to use variable or constant RBE in dose calculation for IMPT 
planning. To achieve a better understanding of the influences and advantages that using a 
variable RBE would cause to the quality of the treatments, this study aims to compare 
weighted dose calculated based on constant RBE, to weighted dose calculated based on 
two estimated variable RBE. One of these variable RBEs is derived from Wilkens’ model 
(J. J. Wilkens and U. Oelfke), and the other one is planned to be calculated based on data 
derived from Guan’s experiments to determine LET and its respective tissue parameters 
(Guan et al.). Subsequently, by comparing worst case doses representing worst case 
scenarios based on RBE model parameters (variable RBE models), this study will 
incorporate uncertainties of IMPT treatments within the RBE models that are under study 
while it tries to determine whether the proposed models are accurate enough to be used in 
optimization of treatment plans. Moreover, three IMPT plans which are going to be 
optimized based on the three RBE options are going to be compared to ultimately decide 
whether the accuracy and improvements in quality of the treatments planned using such 
approach justifies using a variable RBE, and if the proposed RBE model functions 
superior to other variable models. 
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Our study will provide important data for future variable RBE based treatment 
planning that possibly leads to improved therapeutic ratio for cancer patients. Tools 
developed in this study will be used to guide and validate novel treatment planning 
approaches, such as robust optimization toward RBE uncertainty, distal edge avoidance, 
use of more beams, etc., which ultimately ensure sufficient dose to target while reducing 
possible toxicities in normal tissue. 
1.5 Organization 
In the next chapter a comprehensive literature review is presented from 
emergence of radiation therapy to the most recent RBE calculation methods. The review 
mostly focuses on the RBE and its long way from the past until today. After the literature 
review, a description of the procedures and methods that are used during the study is 
presented in chapter three, as well as the details of the steps mentioned above. The results 
and conclusions will be presented in chapters 4 and 5, and finally the future work is 
discussed in chapter 6.   
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Chapter 2  
Literature Review 
2.1 Radiation Therapy  
One of the approaches to cure cancer tumors is radiation therapy. Traditional 
methods of radiation therapy use x-rays, gamma rays, and electron beams while newer 
methods for radiation therapy promotes use of proton particles in radiation of cancer 
cells. In radiation therapy the goal is to produce maximum damage for tumor cells and 
spare the healthy tissue around it as much as possible simultaneously (Terasawa et al.). 
Charged particle radiotherapy was put into consideration and use since 1954 
(Terasawa et al.); and it has come a long way. According to an article on precision of 
radiotherapy (Dutreix), the start to using photon beams as a new approach of radiotherapy 
as opposed to conventional X-rays, occurred in early 1950s and it continued to advance 
in using computers and diagnostic imaging. Also, at the very first years of implications, 
the target volume was considered a rectangular shape. That means the shape of the tumor 
was not being considered as it is but as a constant shape that was feasible for the 
approach.  Yet the most important issue according to mentioned publication has always 
been the difference between the prescribed dose, delivered dose to the tumor, and the 
effective absorbed dose to the target volume. At that time, the only factors considered in 
dose effectiveness in regard to absorbed dose were patient positioning, patient 
immobilization and setting of machine parameters; however, the variations of biological 
effects are considered in regard to delivered dose uncertainty which is considered to be 
acceptable if between ± 5%.  
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Relative biological effectiveness – also known as RBE – is a ratio indicating 
biological effectiveness of one ionizing particle in regard to another ionizing particle 
when the same amount of energy is absorbed. Often we need the RBE of a particular 
charged particle relative to a reference particle for which the biological effects are known 
better. The above definition is correct, however, it might be over simplified as RBE 
depends on various factors for different particles. Although all of such factors cannot 
always be considered while determining RBEs for different particles, depending on the 
information available, some or most of these factors can be used in calculations. Also, 
due to complicated calculations needed for determining RBE, sometimes a constant RBE 
is used. Using constant vs. variable RBE will be discussed further in present review; 
since one of the major goals of this review is to show the differences between variable 
and constant RBE and the reasons behind choosing one over another.  
RBE is mostly useful for calculating the dose which should be implemented 
during radiotherapy sessions. Dose has two different meanings in radiotherapy. 
“Prescribed dose” clearly is the dose that is prescribed to be delivered to the patient, 
while “absorbed dose” is the dose that is actually being absorbed by the target cells. The 
latter is the important value for us in order to determine the actual energy that is received 
by the tissue and the damage that this energy is causing both for tumor and normal 
tissues. So the absorbed dose is considered to determine biologically effective dose.  The 
biologically effective dose is described as 
Biologically effective dose = RBE × radiation dose                                  (1)  
in equation (1) (Terasawa et al.).    
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2.2 Proton Therapy 
Heavy charged particles can produce a dose distribution throughout the target 
volume that has a spread Bragg peak meaning the high dose will include all the target 
volume. This ability also lets the dose to spare the healthy tissue around the tumor which 
prevents the radiation to harm the normal cells. The radiation will enter the target with a 
moderate speed and will slowly rise so that the dose delivery will be the maximum near 
the end of the range. Unlike photon beams which can only optimize two dimensions for 
different treatment beams, proton beams have the ability to optimize the 3D dose 
distribution to the tumor (Miller). At the time, the method used for proton therapy was 
passive beam spreading according to Miller.  
According to the study conducted by Miller, since the stopping point of proton 
beams is important in proton therapy treatment planning, and also because the tissue 
surrounding the tumor has to be spared precisely, the uncertainties have to be considered 
and analyzed. The physical characteristics of proton beams in the field of  proton 
radiation therapy is more certain that their radiobiological properties but the researches 
are on their way to find out more about biological effects of proton beams. According to 
Miller et al. the optimization of proton therapy treatment plans in four dimensions in the 
future can elevate the effectiveness of the treatment.  
A new method for proton therapy in introduced by (Lomax). In the mentioned 
study, a 3D localization of dose is suggested. Using an individual Bragg peak pencil 
beam for each target unit, a homogenous dose distribution can be delivered to the planned 
target volume. (Brahme, Källman and Lind) presented a procedure to optimize the pattern 
of scanning for spot scanning beam method to achieve the planned dose distribution 
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inside the target volume. Additionally, (Carlsson, Andreo and Brahme) has developed a 
similar method to Lomax, using Mote Carlo simulation calculations. All of mentioned 
studies presented the Intensity Modulated proton therapy method for proton therapy.  
Later in 2001, Oelfke introduced a method for photon and proton radiation 
treatment planning, called “Inverse Planning”. An optimization approach for the 
mathematical model of the problem (clinical objectives) is discussed (Oelfke and 
Bortfeld). In 2004, Nill, Bortfeld, and Oelfke compared two techniques of Distal Edge 
Tracking (DET), and the 3D scanning for dose delivery practicing inverse planning (Nill, 
Bortfeld and Oelfke). The Bragg peak of is located at the distal edge of the target volume 
in DET, while the Bragg peak of the dose distribution is positioned inside the target 
volume as well as the distal edge in the 3D technique. The comparison result was that 
DET uses less number of spots and therefore less calculation time than 3D scanning 
technique. However, the beam spots for both delivery systems can be reduced with a 
slight difference in the dose distribution. The quality of the treatment was measured to be 
better in 3D spot scanning method, though, as mentioned before DET can be almost as 
good as the 3D method with less number of beam spots. Although inverse planning for 
IMPT is believed to be a very fast and optimized algorithm for dose calculation, the 
journey to the best treatment planning approaches is not finished yet. Since the physical 
dose calculation still carries a considerable amount of uncertainty and factors that are not 
considered. Physical dose calculation overlooks the actual effect of the beam to the 
target. The local energy spectrum should also be considered.  
The radiobiological effect caused by proton beams are currently considered to 
have the constant value of 1.1 relative to Cobalt 60 according to (Paganetti et al.) and 
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(Gerweck and Kozin). However, in order to achieve treatment plans with more accurate 
absorbed dose calculations, and with the increase in the available data from proton 
therapy patients, considering the RBE in optimization process might be reasonable.  
2.3 Relative Biological Effectiveness 
A constant value of 1.1, expressed in (Paganetti et al.), is used for RBE of proton 
beams. This was justified based on the fact that the existing uncertainties attached to RBE 
are large compared to the methods available for determining RBE value. The 1.1 value is 
derived from experimental data relative to reference radiation of Cobalt 60.  
Gueulette et al performed an experiment on thirteen mice to analyze the impact of 
depth on RBE of 200-MeV proton beams. RBEs were calculated using modulated and 
unmodulated beams at the beginning, middle and end of the spread out Bragg peak. 
Cobalt 60 was used as the reference and the RBEs were found to be equal to 1.16 ± 0.04, 
1.10 ± 0.03, 1.18 ± 0.04, 1.12 ± 0.03, and 1.23 ± 0.03 which were more that constant 
RBE of 1.10 at all depths. Also the RBE increased where the dose decreased. In this 
study, no relationship between depth and RBE values were found. (Gueulette, Böhm, et 
al.). Later in 1998 however, (Gerweck and Kozin) found that RBE of protons increase 
with the depth increasing. Moreover, in this study the constancy of RBE around the 
central axis, RBE as a function of dose, and dependency of RBE to target cell tissue 
properties (α and β) using modulated proton beams is analyzed. The results showed that 
RBE increased when dose decreases, which was found before in former studies, and also 
suggests that the RBE is dependent on α/ β ratios of tumor cells, concluding constant 
RBE of 1.1 especially for tissues with low α/ β ratios is too low for those tissues.  
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In 2001, a study was conducted by (Gueulette, Slabbert, et al.), that evaluated the 
impact of dose fractionating on biological effectiveness. This study used intestinal crypt 
regeneration in mice as the experiment tissue, and Cobalt 60 was considered the reference 
for RBE. The fractions were defined as one, three and ten every 3.5 hours with a 7cm 
Bragg peak for the proton beams. The results for respective fractions were 1.15 ± 0.04, 
1.15 ± 0.05, 1.14 ± 0.07 for corresponding 10.0, 4.8, and 1.7 (Gy). The conclusion was 
that after 10 fractions, more proton irradiations were more effective. Also, it was found 
that the RBE was irrelevant to fractionation up to ten fractions. However it is not proven 
if it goes up or stays unchanged with for higher number of fractions. A sloping depth 
dose curve is advised to be considered in places nearer to the end points of the target 
tissue. Also this study mentions the importance of noticing the values for RBE which are 
more than 1.1 which is being used.  
According to Paganetti et al. no need for changing the value of 1.1 for RBE in 
proton therapy treatment planning is observed (Paganetti et al.).  In this study, the results 
from In vivo and In vitro experiments are evaluated to determine the variations of RBE in 
regards to LET, dose/fraction, and tissue specific parameters. The average value for RBE 
for the mid SOBP is reported to be about 1.2 and 1.1 for in vitro and in vivo respectively, 
ranging from 0.9 to 2.1 and 0.7 to 1.6. An increase in RBE values is reported in relation 
to decreasing dose per fraction. The most important result however, is noticing a 
substantial increase in RBE values within 1 -2 mm from end of the range. The results of 
RBE values are evidently showing a difference with the used value of 1.1, but the study 
suggests that since the uncertainties regarding RBE calculations are currently high, 
calculating tissue, dose, or LET specific RBE will not be practical. It is been proposed 
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that the hot region at the end of the tumor range be considered as a variation region for 
biological effectiveness in treatment planning.  
Although the studies performed on necessity of considering a variable RBE in 
treatment planning and the factors on which RBE might depend, expressed a highly 
uncertain environment for determining RBE, newer researches have been done 
considering RBE as a variable factor. Additionally, efforts began to be done to calculate 
variable RBE. Considering the fact that former studies on continuing use of constant RBE 
of 1.1 for proton therapy was performed when passive scattering beam delivery methods 
were used to deliver the prescribed dose to patients.  
The dependence of RBE on LET, dose, and tissue parameters are confirmed 
according to mentioned studies, and in many research papers including (Jan J. Wilkens 
and Uwe Oelfke), (Gu et al.), etc. the authors attempted to come up with new methods to 
calculate dose and LET and gather and use tissue specific parameters to calculate RBE.  
Also the difference in application of constant and variable RBE in RBE weighted 
dose (RWD) is analyzed by Frese et al., using simulation data from four patients (Frese et 
al.). This study evaluates three treatment plans (physically and biologically optimized 
considering LET and tissue parameters). The RWD was more sensitive to LET in radio 
resistant tissues as compared to radiosensitive target.  
Wilkens and Oeflke suggested a method to calculate RBE (J. J. Wilkens and U. 
Oelfke). In this study, RBE is considered to be dependent on dose, target tissue 
parameters, and linear energy transfer.  
Tissue parameters are usually called α and β, and characterize the response to any 
different radiation that is specifically is the outcome of the combination of the radiation 
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and the tissue type. In other words, any different cell type (e.g. bacteria cells, eukaryote 
cells) responds to the radiation differently. This response reflects itself by the means of 
cell survival fraction.  
The LET is calculated based on (Jan J. Wilkens and Uwe Oelfke) ,a previous 
publication from same authors, which calculates LET using an analytical approach as an 
alternative to using Monte Carlo simulations to determine the LET. The linear quadratic 
model is used to characterize the biological effect in order to calculate RBE. Using the 
evidence on dependence of tissue specific parameters on LET (Tilly), α is indicated as a 
function of LET. β is defined equal to βx (β parameter for reference beam). Using LET, α, 
and β, two RBE functions are introduced, one including proton beam dose as a variable, 
and the other using SF (survival fraction) and λ (LET coefficient in α function) instead. 
The RBE values obtained from the proposed method is examined against experimental 
data. The calculated values are reported to sufficiently match with the experimental data, 
however, for LETs below 30 KeV/µm (higher SFs), the RBE increases with LET. It 
should be mentioned that both LET and dose are limited due to use of LQ model. Also 
cell survival data used in this study is chosen based on availability. This model reflects a 
basic dependence of RBE on dose, and is able to rapidly reproduce the results, however, 
it suggest that more information on tissue specific data be sought as different tissue types 
have different response to radiation.  
Later in 2005, Wilkens and Oelfke investigated other models to calculate LET 
and biological effects (Jan J. Wilkens and Uwe Oelfke). This paper uses the 
phenomenological model, (J. J. Wilkens and U. Oelfke), and 3D LET calculation method, 
(Jan J. Wilkens and Uwe Oelfke), to use RBE and LET calculation in the process of 
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optimizing the treatment plan. New dose and LET functions are introduced and dose per 
fraction is considered in LQ model rather than total dose. The new objective function 
biologically optimizes the treatment plan rather than optimizing the physical dose. Since 
the tissue parameters used in this study are considered not to be absolutely relevant to the 
ones in in vivo experiment, meaning the values calculated should not be considered as an 
absolute value for RBE. It is mentioned in the paper that in some cases the values have 
been over estimated. Also, the LET distributions depend on the scanning techniques and 
LET distributions affect biological effect. On the other hand, the proposed method 
provides tools to identify dangerous situations in regard to organs at risk since the 
biological effect is being optimized and implemented in updating objective function.  
Linear Energy Transfer is in fact a way of demonstration of the local energy 
spectrum of protons within the target tissue. It is also referred to as the radiation quality.  
LET is calculated using Monte Carlo simulations. Also dose averaged LET which is 
mostly used to relate cell survival to RBE dependence on depth can be calculated from 
“the weighted sum of range-shifted Bragg peaks” (Wouters et al.) . 
Monte Carlo simulation modeling was used in a study done by Guan et al., to 
address the biological effects of proton beams delivered by scanning method and 
decrease the uncertainties (Guan et al.). The surviving fraction was found to be complex 
and nonlinear and the cell death, dose and LET is found to be related in a non-unique 
way. This study suggests further implication of this approach to generate data used to 
optimize treatment plans considering a variable RBE.  
Our purpose is to develop an RBE calculating function based on the tissue 
specific data from Guan et al. study. The approach used in this method is to fit the tissue 
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parameter with the given LET values and find a sufficiently similar fit for α and β and 
develop the RBE function using the biological effect function. Then the values will be 
compared to (J. J. Wilkens and U. Oelfke) and constant RBE to evaluate the method.  
Although the current implementation of proton therapy still considers a constant 
RBE value in treatment planning, and the uncertainties in regard to RBE of target tissues 
are significant, we aim to evaluate the impact of using variable RBE in treatment 
planning, using experimental data, phenomenological and analytical models to compare 
the values. Our goal is to achieve a more relevant, more precise estimating method for 
RBE to use in optimizing the treatment plans.  
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Chapter 3  
Methods 
For a cancer radiation therapy treatment plan, the treatment effectiveness 
measurement is not reflected in physical prescribed dose, since every tissue with different 
cell types responds differently to treatment. That means delivered beams do not cause 
exact same amount of damage to different cell types. This is important when optimization 
of treatment plans is anticipated by the cancer treatment facilities. However, due to 
limited available data, presence of inconsistency in available data, and large amount of 
uncertainties, the response of different cell types to proton beams is rather approximated 
with a constant 1.1 relative to photon effectiveness. When it comes to use of proton 
particles in cancer radiotherapy, although the delivered beams are considered to be more 
effective than previously used beams (like beams produced using photons), there are 
inherent potentials in proton therapy that are not fully being developed. In IMPT, the 
treatment has the capability to be optimized incorporating biologic effectiveness of 
proton beams with respect to specific cell types, Dose, and Linear Energy Transfer. 
Based on new experiment done by Fada Guan and his team, we introduced a model to 
estimate RBE values along the beam path for special cell types using the data derived 
from their experiment results (Guan et al.). The model is compared to Wilkens and 
Oeflke RBE model (J. J. Wilkens and U. Oelfke), as well as the constant RBE to observe 
and analyze the results produced using all three models. Several experiments regarding 
model sensitivity and ability to accurately estimate RBE values for three RBE models are 
performed. Significantly, the present study provided important information regarding 
 20 
 
analytical RBE model and its behavior when constant or linear biologic parameters of the 
tissue are used. This information can be used to further underscore the importance of 
using variable RBE instead of the constant 1.1 in cancer proton therapy. The results also 
provide a rather clear image regarding the possible fluctuations of RBE when LET 
increases. An analysis is done to evaluate the behavior of the RBE function in response to 
changes in LET, and tissue parameters. 
3.1 Introduction 
Interest in using particles in radiation therapy treatments has been increasing in 
United States over the current decade (Guan et al.). This interest is based on the 
properties of Protons that allow them to spare the normal tissue from excess radiation to a 
great extend when used as the radiation beam in treatment. Protons lose their energy 
when travelling through tissue, and this energy transfers to the cells. The energy transfer 
rate increases with depth when the speed of the particle decreases. Therefore, the dose is 
the highest near the end of the range and it is called the Bragg Peak. This characteristic of 
proton beams is used to produce a conformal and homogenous dose distribution using 
several beams by modulating the delivered dose of each beam with respect to the 
preference of the volume shape.  
Intensity modulated proton therapy (IMPT) is a powerful tool to deliver 
homogenous dose distributions to tumor cells while sparing the normal tissue around the 
tumor by limiting the dose delivery to adjacent organs at risk. While IMPT delivers such 
goals to a great extent, it does have high sensitivity to range uncertainties and setup 
variations. In addition to delivery uncertainties, it is discovered that the proton beams 
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effectiveness is not constant and changes throughout its path into the tumor and OARs. 
Such variation adds to the uncertainties of IMPT.  
Protons have higher RBE than formerly used photons, so they can be more 
effective in causing tumor cell damage. This would be an important factor when treating 
radio resistant tumors. Proton RBE is considered spatially invariant and a constant value 
of 1.1 relative to photons. While as mentioned in Literature Review chapter, it is proved 
that Proton Relative Biological Effectiveness changes with depth of the beam, dose per 
fraction, and tissue type, the constant RBE of 1.1 is still justified to be clinically used due 
to limited available data needed for modeling the RBE function. One important factor to 
consider as a reason for re-evaluating the usage of spatially invariant and constant RBE, 
is that although many in vivo and in vitro experiments have found out that proton RBE is 
very close to 1.1 relative to reference beam (e.g., X-rays), those experiments have been 
conducted using older beam delivery methods. Using the new scanning beam delivery 
method, Guan et al. experiment has shown different results than former studies on proton 
beam behavior with respect to different tissues. Additionally, even in in vitro and in vivo 
experiments, RBE shown an increase at the end of the range which makes further 
research on proton RBE and delivering models to calculate its values, crucial to IMPT 
improvement. Therefore, methods for three dimensional RBE calculation is needed to 
approximate RBE values such that variations of biological effectiveness of proton beams 
be incorporated in treatment plans. Specifically when optimizing treatment plans with 
inverse treatment planning, calculating RBE values and then optimizing based on the 
calculated RBEs for more accurate dose distribution would play an important role.  
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To be able to model Relative Biological Effectiveness of proton beams, the 
factors that influence this value have been derived and studied over the years. 
Researchers found strong dependency of RBE to Dose per fraction, the energy spectrum 
of the beams which are ultimately characterized by Linear Energy Transfer, and the tissue 
specific parameters.  
In Intensity Modulated Radiation therapy, the main effort is done to place the 
maximum strength of the beams inside the target volume, when the adjacent organs are 
safely spared at the same time. Proton beams maximum energy is delivered to the target 
at the end of their range and this suitably enhances treatment planning to preferably place 
the maximum energy (Bragg Peak) inside the target. Using this characteristic of proton 
beams, a highly homogenous dose distribution can be produced to cover all of the target 
volume range with the maximum effectivity using multiple Bragg Peaks of controlled 
beams. That means many beams are used to form the dose distribution and the 
contribution of each beam is modulated using a weight.  
In calculating RBE all of influencing factors should be considered. Yet, an 
approach should be chosen such that the calculation of RBE could be done relatively 
quickly, since the ultimate purpose of the calculated values are for them to be 
incorporated in the optimized treatment plans and therefore, the calculation and 
optimization process should take a reasonable time and effort in order for the physicians 
to be able to practically implement the method. Accordingly, comprehensive models with 
relatively short calculation time requirement are in priority to be studied.  
On the other hand, if variable RBE is to be used in treatment planning in the 
future, the significance of the difference caused by implementing the variable RBE in the 
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treatment effectiveness should be stablished. In other words, the constant RBE 
implementation in proton therapy treatment planning should be proved inaccurate and 
therefore not justified as this approach imposes much less expenses to the planning 
process. That means while the 1.1 value currently used for proton RBE is proved to not 
be always the case and variability of RBE is established, the effect of considering the 
biological effectiveness variable when planning proton therapy treatments, should be 
proved to be significant enough, and the RBE values should be shown to be different 
enough from 1.1 throughout the beam path, that putting the required resources (time, 
research resources, computation capacity, etc.) in calculating RBE and optimizing 
treatment plans with regard to the calculated RBE values, be justified. In order for new 
models to be developed, as mentioned before, reliable data regarding the relationship of 
proton beams, their energy, and the behavior of target tissues is needed. However, all of 
the former available data were inconsistent and included large amount of uncertainties. 
This was due to limited studies on proton beams, limited access to beam, experimental 
settings, and equipment calibration differences, as well as difference in reporting the 
results. Therefore, developing accurate models to calculate RBE while considering all of 
the influence factors has been challenging. Especially since scanned beams are becoming 
to be used more and more as the dose delivery methods, and former studies have been 
based on data which was derived using the passive scattering proton therapy, or high dose 
per fraction (as examples of older dose delivery techniques), the importance of 
availability of proton biological effectiveness information, has increased. Fortunately, 
Fada Guan and his team, have been experimenting on proton radiobiological 
effectiveness. In their recent paper (Guan et al.), the biologic effectiveness of scanned 
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proton beams is mapped and the biologic uncertainties are tried to be minimized to 
accurately reflect the results of the experiment. The details regarding Guan’s experiment 
will be discussed further in next sections. LET vs. tissue parameters’ relationship is found 
to be nonlinear especially toward the end of the range, and higher LETs. Data points for 
such relationship is delivered as the result of the experiment, approximating the RBE 
values of proton beams for Lung Cancer cells. With the results from the mentioned 
experiment, a new window is opened to further investigate in proton beam biologic 
effectiveness. Delivering and experimenting RBE models based on this newly available 
data is an interesting way to implement such information with the purpose on improving 
treatment effectiveness and quality. Accordingly, the purposed of this study, is to choose 
appropriate variable RBE models to compare with the constant RBE, and to re-evaluate 
the continued use of 1.1 as the proton RBE. Additionally, the sensitivity of the models is 
observed with regard to changes in tissue type parameters for both reference radiation 
and proton beams. For this purpose, Wilkens’ phenomenological model for relative 
biological effectiveness is chosen to be used as an original model that the proposed RBE 
is compared to. Guan experimental data is used to model the dependency of tissue 
parameters to LET independently to each other. Using this relationship, an RBE model is 
suggested and examined against constant and Wilkens’ RBE. The differences between 
the three models are measured based on Cumulative Dose Volume Histograms, which 
illustrate RBE weighted Doses for all three models.  
To calculate RBE values realistically, dose contributions to every voxel of target 
and organs at risk is needed. For this matter, three brain tumor cases are selected from 
patients who have received IMPT and clinical treatment. Dose and Linear Energy 
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Transfer from all beamlets to all voxels are calculated using Monte Carlo Simulation. The 
RBE values and RBE weighted dose of all three models is calculated for all three 
patients, and dose volume histograms are used for comparison purposes and results 
demonstration. The sensitivity of two variable RBE models to tissue specific parameters 
for reference radiation, and the sensitivity of the RBE model based on Guan et al. 
experiment data to the tissue parameters fluctuations with regard to proton beams, is 
observed and analyzed.  
The organization of this chapter is as follows: The key information and definitions 
that are used in this report, are introduced and defined in section 3.2. RBE definition and 
characteristics is presented, and its role in IMPT plans is discussed. The tools and 
concepts used to model RBE, calculate the results, and carry out the comparison are 
introduced and illustrated. In section 3.3 RBE models are discussed in details including 
the reasons for being chosen and the rationale of developing the models. In the next 
sections, methods and calculations are demonstrated. 
3.2 Preliminaries of Relative Biological Effectiveness  
As discussed before, the physical dose is not necessarily an appropriate variable 
to be optimized during treatment planning as it does not represent the actual effect on the 
target cells in radio therapy. The reason for this is clearly lays in the variant nature of the 
target, meaning that a delivered or prescribed dose can evoke different responses from 
different tissues. The variation in response also can be caused by the linear energy 
transfer of the delivered dose at different areas in the target. To more elaborate on 
variable factors that influence on biological effect, which will be discussed mostly under 
relative biological effectiveness, one can look into mentioned agents in second chapter. It 
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is mentioned that RBE is dependent on dose, depth, and tissue specific parameters called 
α and β. It should also be noted that depth alone is not the effective factor and the energy 
spectrum of the proton beams is the factor. The energy of the proton beams which differ 
along with their movement into the target volume can be presented by linear energy 
transfer.  
3.2.1 RBE Characteristics and Definitions 
Treatment Area  
Radiotherapy is a treatment that is localized in patient’s body that means the 
treatment does not affect the whole body of the patient. Therefore, the definition of tumor 
and target volumes, and correctly locating the treatment is absolutely critical to the 
success of the treatment. 
The patients’ cells in treatment planning area are divided into two general 
categories, which are called “Target Volume” and “Organs at Risk”. The area under 
radiation is also divided into many small areas in the 3D space. The radiation is delivered 
to the destination volume using a location defining unit called voxel. Voxels are the small 
three dimensional areas that are considered the unit of volume. Each voxel in treatment 
planning process is addressed with three indexes, I, J, and K that describe the voxel’s 
location is space. Target volume and Organs at Risk are distinguished in the treatment 
plans using this voxel information (Burnet et al.).  
Three main structures (volumes) that are considered in radiotherapy planning. 
Gross Tumor Volume (GTV), is the extent of the gross tumor. This is the volume that is 
observable in imaging and the easiest to define. The second volume is the un-imagable 
spread of tumor that surrounds the GTV. This sub-clinical disease spread margin around 
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GTV, is known as the Clinical Target Volume (CTV). CTV is important because it 
should be considered in treatment planning such that adequate treatment is delivered to 
the volume for it to be cured. This part is challenging since CTV cannot be adequately 
defined. In some cases however, CTV is not surrounding a GTV necessarily, as there 
might be another CTV in another location. This means the density of tumor cells in that 
area is lower. Accordingly, it is assumed that lower radiation should be delivered to CTV 
to cure the disease. Planning Target Volume (PTV) is the area that includes CTV and 
GTV usually with an additional margin to allow for uncertainties in planning or 
delivering the treatment. PTV is rather a “geometric concept” which is designed to ensure 
that the treatment is actually delivered to CTV.  
 
 
Figure 2  Illustration of the main radiotherapy planning volumes. (Burnet et al.) 
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When radiation therapy treatment is delivered to the target area, the healthy 
tissues that surround the tumor are in the danger of tissue damages and depending on the 
sensitivity of that areas, the treatment plans are adjusted to and influenced by such 
sensitivities. To spare these normal tissues, a margin is added to OARs. Adding a margin 
to OARs is sometimes challenging since such margins might ultimately add to the OAR 
volumes and intervene with the planning target volume. 
 
 
Figure 3 Planning CT showing the visibility of GTV, margin for microscopic spread of the tumor (CTV), and marginal 
PTV (Burnet et al.). 
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Radiobiological effect 
 
 
Absorbed dose effect to the destination tissue is reflected in cells survival 
fraction. That means the relationship between the fraction of cells that remain 
reproductive and healthy when radiated, to the total seeded cells with dose. This 
relationship is illustrated by a most frequently used quadratic model. The cell survival is 
characterized by two tissue specific parameters that are known to depend on dose of the 
beams and the biologic properties of the target tissue. Equation (2), illustrated as  
SF = exp ( αDβD
2
 )                                                 (2) 
shows the relation between tissue parameters, dose, and Surviving Fraction (SF), and is 
called the Linear Quadratic model developed by Kellerer and Rossi. Equation (3), using 
tissue parameters and dose, characterizes the biologic effect as  
𝜀 =  𝛼𝐷 + 𝛽𝐷2.                                                 (3) 
Biologic Quadratic model indicates that the biologic effect of a particular beam depends 
on the dose and the tissue parameters of the target cells. As a result, it is more desirable to 
Figure 4 illustrates the structure definitions and their schematic locations inside treatment area. 
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optimize the biological effect instead of the dose alone when optimizing the treatment 
plan. Such methodology is important in the sense of effectiveness of the treatment and 
sparing the organs at risk. Later the biologic effect relationship is used to define the RBE 
model. 
Beam Weights 
Intensity of proton beams is modulated to form a homogenous dose distribution 
throughout the tumor volume in IMPT planning. This is done by multiplying specific 
optimized weights for every voxels in the corresponding dose for that voxel.  These 
weights are referred to as Wj which denotes the relative fluence weight of beam spot j. 
That means the contribution weight of the beam spot j to the total dose contribution to the 
destination voxel.  
Dose Dependency 
RBE depends on the dose per fraction of the beam. As mentioned before, in 
several studies, it is observed that RBE changes when dose changes. As a result, dose is a 
variable factor that effects on RBE value of the beam. To monitor the variabilities of 
RBE inside the target volume and OARs, RBE for every volume unit should be 
calculated since the dose distributions are calculated in every voxel, when treatment plans 
are optimized. In this study, RBE for the target tissue and the organs at risk for the three 
models is calculated for every voxel. For this matter, the dose contribution of every beam 
spot to every voxel in IMPT plans should be known when RBE for every voxel under 
radiation is calculated.   
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Linear Energy Transfer 
The biologic response of the target cells to the radiation depends on the energy 
spectra of the radiation at the target. Basically, the effect is sensitive to the amount of the 
energy that the beam is delivering to the target while passing through it. Such effect is 
characterized by Linear Energy Transfer (LET) also known as Radiation Quality. LET is 
the amount of energy the beam transfers to voxel of the target volume, per distance unit. 
LET depends on the entrance energy of the beam, and is related to the type of tissue it is 
passing through. LET of a particular beam with respect to a cell line, can be determined 
by experiment. Many experiments are conducted to see the biologic response of specific 
cells when LET changes. This type of experiments provide important information 
regarding the behavior of α and β with regard to increase of LET. More on this topic is 
provided when Guan’s experiment is discussed.  
  After knowing the tissue parameters’ relationship with LET, Monte Carlo 
simulation or analytical approached can be used to determine the LET of the beam under 
study. Wilkens and Oeflke developed an analytical model for calculation of proton LET 
distribution, considering the initial beam energy and the initial energy spectrum. This 
method is a fast method to be used in RBE calculations (Jan J. Wilkens and Uwe Oelfke).  
Since the target volume is divided by three dimensional unit cubes (voxels), the linear 
energy transfer of the beam for every volume unit should be known. We used Monte 
Carlo simulation to spatially determine the LET of each beamlet for each voxel. Then, 
LET and dose calculation method presented in Wilkens and Oeflke’s paper , shown in 
equations (4) and (5) 
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𝐷𝑖 =  ∑ 𝐷𝑖𝑗
𝑁
𝑗=1 𝑤𝑗   .                                                         (4) 
 are used to determine the total dose (Di) in voxel i, and the total dose averaged LET in 
voxel i from beam spot j (Li) (Jan J. Wilkens and Uwe Oelfke "Optimization of 
Radiobiological Effects in Intensity Modulated Proton Therapy"). In the above equation, 
wj denotes the “relative fluence weights” of beam spot j, when we consider N beam spots, 
and Dij denotes the dose contribution to voxel i per unit fluence of beam spot j. Di  then 
will be the total dose in voxel i. The total dose-averaged LET in voxel i is given as: 
For    Di > 0 , 
𝐿𝑖 =  
1
𝐷𝑖
 ∑ 𝐿𝑖𝑗𝐷𝑖𝑗𝑤𝑗
𝑁
𝑗=1 .                                                                          
(5) 
Dose Volume Histogram 
In radiation therapy, dose distributions are generated in a computerized treatment 
planning systems. In such systems, three dimensional dose distributions are the 
reconstruction of a CT scan from the patient. The dose volume histogram can be used in 
differential DVH or cumulative DVH types. DVH is generated by determining the size of 
the dose bins of the histogram, then the cumulative DVH is plotted when dose bins are 
shown along the horizontal axis, and the high of the bins represent the volume of the 
structure that is receiving that dose or higher. The volume can be the target volume or 
normal tissues. In fact DVH relates the radiation dose to tissue volume and summarizes 
3D dose distributions in a two dimensional format. Usually a dose volume histogram 
includes all of the structures in one plot and each structure is shown with a different color 
than the other ones to demonstrate the shape and the percentage of the volume that is 
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under the shown dose of radiation (the vertical axis usually shows the fraction of volume 
rather than the absolute volume).  
DVH is a strong tool used to observe and analyze the dose to volume. However, 
because the purpose of DVH is to show the 3D dose distribution in a 2D histogram, no 
spatial information is provided in it.  
 
 
Figure 5  Cumulative Dose Volume Histogram of a radiation for five different structures, representing the RBE*Dose   
with respect to fraction of volume. 
 
Dose volume histograms are widely used in this study as the measurement tool for 
determining the differences between every scenario including comparisons between 
different RBE models for same patient, and between the RBE*Dose values when tissue 
parameters are changed to observe the sensitivity of a model. The reason for choosing 
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DVH as our measurement tool is that the data from the calculated values of RBE and 
Dose*RBE is so large in amount even for one scenario itself, that the comparison 
between scenarios would be extensively hard if not impossible. On the other hand, DVH 
provides us with useful illustrations of the driven data and makes comparisons and 
conclusion significantly easier. Furthermore, it provides the benefit for us to see the 
meaningful differences and trends quickly.  
3.2.2 Study Steps 
In this study, we aimed to investigate the impact of recently developed RBE 
models on intensity modulated proton therapy (IMPT) treatment plans. The difference 
between variable and constant RBE weighted doses in retrospectively selected proton 
patient cases is demonstrated. The uncertainties in RBE model parameters in the same 
patient cases are also analyzed. To deliver the mentioned goals, three brain tumor cases 
are chosen from the brain cancer patients who have received IMTP and clinical 
treatments. The tumor volume location information and the prescribed dose information 
that was calculated based on constant RBE for the three patients is exported. To achieve a 
treatment plan in which the biological effect is optimized rather than the physical dose 
alone, three dimensional LET and RBE values should be calculated first, so that the RBE 
values are determined based on dose and LET values that are specific to each voxel. 
Using all planning target volume information and OARs definitions, and the dose 
contribution of each beam spot to each voxel (calculated using Monte Carlo Simulation), 
the total dose for every voxel and dose averaged LET is calculated. In the next step, RBE 
and RBE*Dose for both of the variable RBE models for every patient are calculated. The 
differences are illustrated using cumulative dose volume histograms. The sensitivity of 
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two variable RBE models to tissue parameters both for reference radiation and proton 
beams changes is studied and shown in multiple DVHs.  
3.3 RBE Models 
3.3.1 Choice of RBE Studies 
The rationale for anticipating a variable RBE model and making efforts to 
develop one is based on the presumed practicality of optimization of treatment plans 
implementing calculated variable RBE. That means when modeling the biological effect, 
we have in mind that the model should be quick to calculate, and low in uncertainties. 
However, up to recently, the uncertainties have been an unavoidable part of the journey 
toward developing accurate RBE models. The limited availability of reliable data is due 
to limited beam access for researchers, different experiment configurations, machine 
calibrations, and differences in reporting the results. Moreover, conducting such 
experiments are time consuming. Although RBE models are being developed even with 
limited data, delivering accurate models to estimate RBE behavior with lower levels of 
uncertainties requires that more study be done on the proton beam RBE. As of now, one 
of the most wide accepted RBE models is suggested by Wilkens and Oeflke which is 
called the phenomenological model by the authors. This model presents a simple RBE 
formula based on biologic effect quadratic model. The goal behind delivery of the 
phenomenological model was to provide a model that can be quickly calculate RBE, 
while incorporating all of the influential factors on the RBE such as dose, LET, and tissue 
specific parameters. In the mentioned study (J. J. Wilkens and U. Oelfke), it is discussed 
that the optimization of treatment plans based on variable RBE should be done within a 
time that is applicable by clinical frameworks. Since the treatment plans are optimized 
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right before the treatment delivery, the presence of the patients and their wait time in the 
facility, as well as time and computational resources can be a concern. Therefore, 
providing a model that can consider variable agents that affect RBE without over 
complicating the calculations seems to be the appropriate approach to take. As a result, 
Wilkens and Oeflke’s model that now we call it vRBE-Wilkens, is naturally the often 
accepted model. However, the data used to model the biological response of tissue to 
proton beams is not focused entirely on proton beams especially in the ranges of interest. 
As a result, the model might not reflect the actual values for RBE due to the conclusions 
made based on that limited data. On the other hand, although vRBE-Wilkens  has its own 
disadvantages that we will discuss further in detail later in this section, it is chosen as a 
measure that the RBE model based on Guan et al experiment will be compared against. 
The values and behavior of vRBE-Wilkens when tissue parameters change, or simply the 
RBE values compared to another RBE is also interesting to assess.   
Our other choice of RBE is one delivered based on vRBE-Wilkens model but 
with a number of modifications. Such modifications are decided to be made, as a result of 
a recent study done by Fada Guan and his team. Guan et al has experimented proton 
beams on cancer cells to determine the response of the tissue to known LET. The newly 
available data provided us with the opportunity to examine new RBE models or 
extensions of the existing ones.  
3.3.2 Wilkens’ Method for Calculating the Variable RBE  
Wilkens and Oelfke proposed a model for RBE calculation which was designed to 
calculate RBE values based on Dose, LET, and tissue parameters while keeping the 
formula simple (J. J. Wilkens and U. Oelfke). This model is defined as a simple and fast 
 37 
 
calculation method for RBE. This study is especially conducted to provide a quick 
approach to estimate RBE in inverse treatment planning for proton therapy when the 
integration of RBE into the optimization process is desired. It should be noted that α, is 
defined as a function of LET within the relevant range of 0-30 KeV/µm, while β is 
considered constant and equal to βx.  This assumption is based on available experimental 
data, which showed that β is invariant with regard to LET values. The results from 
calculations based on this model is in good agreement with experimental data, however, 
as mentioned by the authors, this agreement might be the result of using the same 
experimental data, both for comparison, and for fitting the tissue parameters. The linear 
quadratic model of surviving fraction is used to characterize the biological effect based 
on α and β. The RBE definition is based on the fact that the biological effect of the two 
radiations, which are proton beams and X radiation here, are the same. That means, both 
radiation are causing same biologic effect on a same tissue. On the other hand, the 
biological effect formula proposed in (J. J. Wilkens and U. Oelfke), describes the 
biological effect as a function of dose and tissue parameters. The phenomenological RBE 
is derived by considering two survival curves for two different radiation, as a function of 
dose for the same biological system. Since the definition of proton RBE is the ratio of the 
reference radiation dose to the proton dose that causes the same biological effect at the 
reference dose, if the two survival curves with different beams and same tissue type, be 
put together as equals, then a relationship between proton RBE, dose, and tissue 
parameters for both radiations is derived. 
As the numerical dose values for the reference radiation is unknown when RBE is 
being calculated, using equation (6),  
 38 
 
𝑅𝐵𝐸 =  
𝐷𝑥
𝐷𝑝
 .                                                   (6) 
Dx is substituted by RBE*Dp, in equation (7) 
𝛼𝑋𝐷𝑥 +  𝛽𝑥𝐷𝑥
2 =  𝛼𝑝𝐷𝑝 + 𝛽𝑝𝐷𝑝
2  .                                                         (7) 
The linear dependence of α on LET, and β value are then used to deliver the equation (8) 
𝑅𝐵𝐸(𝐷𝑝, 𝐿, 𝛼0, 𝜆, 𝛼𝑥, 𝛽𝑥) =  
√𝛼𝑥
2+4𝛽𝑥𝐷𝑝(𝛼0+𝜆𝐿+𝛽𝑥𝐷𝑝)−𝛼𝑥
2𝛽𝑥𝐷𝑝
                                                              (8) 
to calculate RBE values. The value for 𝛼0 had then to be determined. To do so, Wilken et 
al. approximated 𝛼0 with equation (9), as  
𝛼0 =  𝛼𝑥 –  0.5 .                                                               (9) 
The final RBE formula to calculate RBE values based on dose, tissue parameters, and 
LET is demonstrated by equation (1), as  
𝑅𝐵𝐸 = −
1
2𝐷𝑝
𝛼𝑥
𝛽𝑥
+ [
1
4𝐷𝑝
2 (
𝛼𝑥
𝛽𝑥
)
2
+
1+
𝜆
𝛼𝑥
(𝐿−0.5)
𝐷𝑝
𝛼𝑥
𝛽𝑥
+ 1] 
1
2
 .                                         
(10) 
 
Equation (8) shows the developed RBE equation. Since Frese and Wilkens considered the 
α0 to be determined using equation (9) in another study(Frese et al.), when implementing 
this relationship to RBE function, the equation that is used in our study for calculating 
RBE values is derived. 
Wilkens and Oeflke used the results for linear quadratic parameters for the 
survival of V79 Chinese hamster cells in vitro. The experimental data that is used to 
determine the dependence of β on LET, was inconsistent and included a large amount of 
uncertainty according to the authors. The relationship could not be determined at some 
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LET values due to unavailability of information in that areas. Also, since the experiments 
were conducted using different cell types, and various experimental configurations, and 
because not all the mentioned experiments used proton beams as the radiation, no 
meaningful relationship could be developed from experimental data. Besides, results 
from experiments demonstrated a rather constant value for β which is decided to be 
assumed equal to reference radiation βx.  
 
 
Figure 6 Experimental results for the LQ parameters for survival of V79 Chinese hamster (J. J. Wilkens and U. Oelfke). 
 
For higher LETs (above 10 KeV/µm), α and β behavior is not clearly known, but 
for lower LETs, the tissue parameters’ relation with LET is considered to be accurate in 
Wilkens and Oeflke’s paper, in which it is found that the RBE is higher for lower doses, 
independent of LET. However, the authors argue that this results pertain to doses above 1 
Gy, and below 10 Gy, and for OARs when the dose is very low, the behavior of RBE is 
not known. 
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3.3.3 Guan et al. Experiment  
Proton relative biological effectiveness is yet to be determined by experiments 
and as mentioned before, one of the obstacles in the way of developing accurate RBE 
models, is the lack of accurate experimental data. However, even with high uncertainties 
in available data, much efforts are being done to model RBE, and while new models are 
considered every day, radiation technology is improving as well. With newer beam 
delivery techniques being used more and more every day, radiation therapy becomes 
more precise and uncertainties are decreasing. The new scanned beam delivery method is 
used in Guan et al experiment to map the biological effectiveness of protons in space. 
Guan argues that former methods for mapping variations of biology effectiveness such as 
high dose per fraction, and passive scattered beams are time consuming and the results 
driven when using the mentioned methods are inconsistent with large uncertainties tied to 
them. Therefore, Monte Carlo modeling and clonogenic survival assays are used to 
determine the biological effectiveness of proton beams with high accuracy and 
minimized uncertainties.  
Guan et al. compared the two delivering methods: passively scanned, and scanned 
beams at three matched locations along the beam paths and found substantial differences 
between the two delivery methods. Passively scattered beams introduce significant 
uncertainty in the relationship between biological effects and LET due to the broad 
energy spectra of these beams and particularly, the long low-energy tails. 
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Figure 7 Comparison of passive scattering beams and actively scanned beams energy spectra (Guan et al.).  
 
A customized device based on Monte Carlo models is designed that shifts the 
range of the radiation in a stepwise manner (consisting of 12 steps), and delivers different 
combinations of dose and LET to samples. Radiation delivery is done using actively 
scanned monoenergetic proton beams, and high throughput clonogenic assays of non-
small lung cancer cells are used to reduce the uncertainties imposed by beam delivery 
method, and biological uncertainties caused by counting and plating. Moreover, 
minimum number of counting steps for a clonogenic assay is used in an attempt to 
remove complicating biological processes from readout of the colony formation. One 
radiation is designed to deliver the dose to all of the samples at the same time to reduce 
the experimental configuration uncertainties and data noises. 96-well plates were used for 
this experiment.  
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Although this experiment provides extremely important data regarding proton 
biologic effectiveness, because the device ended up over sampling the low LET points (5-
10 KeV/µm), and under sampling Of higher ones, later when we fitted this data, the 
distance between data points in higher LETs were rather long. Therefore, tissue 
parameters’ dependence on LET was not shown very precisely by the fitting. However, 
the information is enough to model the relationship and use the dependence function to 
calculate RBE values.  
One interesting finding from Guan et al. experiment was that a nonlinear 
increasing trend was observed at points with high LET values. This is new compared to 
former experimental results which considered α to be linearly dependent to LET, and β to 
be constant and independent of LET. The fit results shown a linear dependency for β to 
LET from low LET points up to 10.8 KeV/µm, then the trend shows a nonlinear 
relationship.  
Figure 8  The device (Jig) and a schematic illustration of how the jig reduces the energy in a stepwise manner 
(Guan et al.) 
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Such differences in experimental data when used to calculate RBE values, would 
cause significant differences, as the calculations for RBE models done for three patients 
reflected such differences. Furthermore, not only different relationships are used, but also 
β is changing with LET. Later in this chapter, the results are discussed with reference to 
the characteristics of the tissue parameters relationship with LET. 
As Guan et al suggested in his paper, direct comparison between studies are 
difficult and may not be valid due to inherent differences in experiments. However, while 
other studies reported a linear relationship between LET and RBE, the results from 
Guan’s experiment and his team show a nonlinear relationship. Since previous studies 
used an average over broad ranges of passively scattered beam for LET values, the 
derived data can yield the same average spectra with different energy and LET values. 
The results from our calculations agree with Guan et al. It is not surprising as we used the 
data from this experiment to model RBE.  
 
Figure 9  RBE vs. LET plot of the Guan et al experiment results (Guan et al.). Blue and red lines show two similar 
types of cell lines’ results for comparison.  
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Oversampling in lower LETs and under sampling of higher LET points is clear in 
the table 1 (Guan et al.). However, even with this data points, the sudden increase of RBE 
in last three data points is apparent.  
 
The trend of α values against LET, fluctuates to higher and lower values when LET is low, and 
then starts to increase considerably with a steep rate, and finally shows a nonlinear increase when 
LET increases. On the other hand, β values hardly fluctuate at low LETs, and the sudden change 
in increase rate and trend occurs after LET = 10.8 KeV/µm. 
Delivering The RBE Model Based on Guan et al Study 
The radiobiological model suggested by Wilkens and Oelfke (J. J. Wilkens and U. 
Oelfke) defines the biological effect as function of dose and tissue parameters, which was 
demonstrated in equation (3). As mentioned before, while calculating RBE, the biological 
effect for both reference radiation and proton beam are the same for the same tissue. That 
means αp, βp, and Dp will have the same ε as αx, βx, and Dx. Knowing this, the right hand 
sides of both equations can be considered as equal, and we can demonstrate the relation 
between the reference beam parameters and the proton beam parameters as the equation 
shown below, with αx , αp, βx, βp, Dx, Dp as variables. As of the total available data, αx, βx, 
Table 1  Alpha, Beta, and LET averages as the ultimate result of Guan et al experiment (Guan et al.). 
 45 
 
and Dp are available, and αp and βp are derived from the experiment outcomes. We are 
missing values for Dx , however, since the purpose is to find a formula for RBE, equation 
(7) is used to replace Dx with RBE*(Dp). 
DX  denotes the absorbed dose of the reference radiation (Cobalt 60), and DP 
shows the absorbed dose of the proton beam in equation (7). In subsequence, the goal is 
to propose a function for RBE based on proton dose, LET, αx and βx as input; α and β for 
proton beam are fitted with their corresponding LET values to achieve the relationship 
between tissue parameters and LET as the variable in the form of quadratic functions. It 
should be noted that the values seen in table below are the averaged value of minimum 
and maximum values for the parameters. The average is calculated by the author for ease 
of use. Although the average values for tissue parameters are used now, later in this 
study, upper and lower limits of the parameters will be considered and used to examine 
the sensitivity of RBE when calculated based on the new proposed model.  
There is a sufficiently broad range of software that can be used for fitting the data. 
For now Excel is used to primarily fit the data and see the progress and report primary 
results. First a quadratic relationship was fitted with the data and the results is shown in 
figures below. However, after evaluating the results for the first patient using a quadratic 
relationship for tisuue parameters, we decided to use a linear relationship for the LET 
values below 10.8, and consider a quadratic fit for the high LET values. Such approach 
would better reflect the behavior of α vs. LET, and β vs. LET functions. Also, since we 
are using Wilkens’ RBE model for comparison, it would be more reasonable to use a 
linear relationship for lower LETs where Wilkens has justified data to assume linear 
relationship for α, then use the quadratic relationship for the rest of the data points where 
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the difference between Guan et al experiment results and other experiment results is 
significant and stands out. 
 
 
 
Figure 10 Quadratic fit for the relationship between Alpha tissue parameters and LET. 
 
 
 
Figure 11 Quadratic fitted relationship to model the relationship between Beta values and LET 
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Figure 12  Linear fit of Alpha parameter vs. LET for lower LET values, and quadratic relationship considered for 
higher LET values 
 
 
 
Figure 13 Linear fit of Beta parameter vs. LET for lower LET values, and quadratic relationship considered for higher 
LET values 
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The multiplying coefficient is used exactly as calculated in the fitting and as shown in the 
figure, however, for linear parts of the tissue parameters, the starting points are scaled 
and moved along the vertical axis to accurately correspond to the organ information that 
are used to calculate RBE and dose.  
For different organs, tissue specific parameters for photons are used to determine 
the entrance point for the fitted curves. Moreover, since the parameters are different for 
OARs, using the photon parameters, the parameter for proton is adjusted. Table 2 
includes the parameter information of photon beams for structures in this study. The 
presented table which was derived from Frese et al. paper (Frese et al.), includes accepted 
values for tissue parameters corresponding to photon beams. 
Note that the structures for all three patients that are used for calculating RBE values 
include, GTV, CTV, brain, brainstem, and chiasm. The later three are the OARs. 
Table 2   Tissue parameters for photons and average dose – volume statistics for target volume and organs at risk  
(Frese et al.)  
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RBE formula is derived by substituting αp and βp with the fit from the Guan et al 
data. Since the relationship is considered to be a two piece function, the calculation for 
that part of the equation is divided into two parts in the program (one for LET<10.8 
KeV/µm, and one for LET ≥ 10.8 KeV/µm). It is important to note that the LET value of 
10.8 KeV/µm corresponds to the Bragg Peak of the beam. This provides important 
information regarding the behavior of tissue parameters before, at, and after the Bragg 
peak. As we can see, the relationship between LET and tissue parameters at LET = 10.8 
KeV/µm changes from almost linear with low steep, to a significantly nonlinear 
increasing trend. By inserting the fit values to RBE equation we have 
For LETs < 10.8 KeV/µm                                (11) 
αx(RBE)(Dp) + βx[(RBE)(Dp)]
2 = [0.0204(LET) + 0.1614 ]Dp + [0.0041(LET) +
0.1197 ]Dp
2 . 
and for LETs > 10.8 KeV/µm                                                                    (12) 
αx(RBE)(Dp) + βx[(RBE)(Dp)]
2 = [0.0116(LET2) − 0.2807(LET) + 2.007]Dp +
[0.0149(LET2) − 0.0349(LET) + 2.183]Dp
2  . 
Therefore, RBE is calculated using as 
𝑅𝐵𝐸 =
−(𝛼𝑥)(𝐷𝑝)+√((𝛼𝑥)(𝐷𝑝))2−4((𝛽𝑥)(𝐷𝑝
2))(−𝑄)
2((𝛽𝑥)(𝐷𝑝
2))
 .                                                        (13)        
             
The values for RBE, dose averaged LET are calculated using GAMS program. 
RBE*Dose values are calculated and plotted for every organ type in DVHs to be 
compared. Although the fit presented above is sufficiently accurate to be used in 
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calculations, more advanced fitting can help the accuracy of the estimations of tissue 
parameters based on LET. An example of a slightly better fit is shown. Specific software 
can also be used for this matter. 
 
 
Figure 14 Fitted Guan et al. experiment data for α and LET, to piecewise linear and quadratic functions 
 
Figure 15 Fitted Guan et al. experiment data for β and LET, to piecewise linear and quadratic functions 
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The presented fitting method in figures 14 and 15, are not used in calculations in 
this study, and have the purpose of suggestion for future studies and fitting improvement. 
The necessity of a precise fitting method, is further underscored and discussed in next 
chapter, when the sensitivity of vRBE-Guan to fit parameters for α and β dependency on 
LET is analyzed.  
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Chapter 4 
Results  
When comparing RBE*Dose values using vRBE-Wilkens, vRBE-Guan, and 
constant RBE for the three patients, vRBE-Guan was observed to have significantly 
higher values than the other two models.  Given the large deviation of the Guan et al 
experiment results from formerly available data on proton RBE, such difference was 
predictable. That means observing higher values for vRBE-Guan can be possibly due to 
implementing a variable β instead of a constant, or the increase of RBE vs. LET after 
Bragg Peak. The role of the β parameter can be significant especially because vRBE-
Guan is compared against vRBE-Wilkens which modeled β as a constant value equal to 
βx. Furthermore, the nonlinear increase of RBE vs. LET suggests that the calculated 
values should also be higher than usually observed trends. As discussed later in this 
chapter, the value of vRBE-Guan is highly sensitive to tissue parameters fluctuations. 
Please note that same method for developing RBE formula is used for both vRBE-Guan 
and vRBE-Wilkens, and the two models are only different in modeling the tissue 
parameters’ behavior. Therefore, if the Guan et al experiment data is close to actual 
behavior of RBE in spite of former experiment data, given that the scanning beam 
delivery method is used in this experiment, and there are no other reliable data besides 
Guan et al results that models tissue parameters’ relationship with LET, it can be 
concluded that this relationship may reflect RBE more accurately.  
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 4.1 Calculated RBE Results 
The cumulative RBE weighted Dose Volume Histograms of three RBE models 
for patient 1 are included and are followed by the DVHs for the other two patients.  
vRBE-Wilkens is referred to as R-Wilkens on the histogram using the dashed lines, and 
R-Guan shown by solid lines, corresponds to vRBE-Guan. Ultimately, R-constant plotted 
using dotted lines, demonstrates RBE*Dose for constant RBE. The three models are 
evaluated in more details as we move forward in this chapter. Colors blue, red, black, 
green, and cyan reflect the histograms for GTV, CTV, which correspond to PTV 
(planning target volume), and Brain, Brainstem, and Chiasm contribute to OARs (organs 
at risk) for all three tumor cases. As observed in the DVHs, the percentage of the target 
volume that receives the maximum dose, is almost 100% for GTV, and CTV, while this 
fraction decreases for other organs. The delivered dose to OARs should be the minimum 
dose possible for the normal tissues to be spared from damaging radiation. Therefore 
lower fractions of volume against relative dose is preferred. 
 
Figure 16  Cumulative RBE weighted dose volume histograms of three RBE model for patient 1. The dashed lines are 
used to show the vRBE-Wilkens, the dotted lines pertain to constant RBE, and the solid lines are used to 
demonstrate vRBE-Guan. 
 54 
 
 
Figure 17  Cumulative RBE weighted dose volume histograms of three RBE model for patient 2. The dashed lines are 
used to show the vRBE-Wilkens, the dotted lines pertain to constant RBE, and the solid lines are used to 
demonstrate vRBE-Guan. 
 
Figure 18  Cumulative RBE weighted dose volume histograms of three RBE model for patient 3. The dashed lines are 
used to show the vRBE-Wilkens, the dotted lines pertain to constant RBE, and the solid lines are used to 
demonstrate vRBE-Guan. 
 
It is concluded form the DVHs, the RBE values highly depend on αx, βx, and 
tissue response to proton beams. Although the real RBE values for proton beams might 
not be as high as the calculated values in this study, the model effectively reflects the 
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Guan et al experiment results in the calculated RBEs. On the other hand, it should be 
considered that vRBE-Wilkens might not accurately or completely reflect the biological 
effectiveness of proton beams effects to the RBE values. Since tissue parameters for 
proton beam are highly approximated by the tissue parameters for reference radiation in 
vRBE-Wilkens model, the biological response of radiated tissue by proton beams are not 
fully present in the formulation, it is not surprising that the RBE values from vRBE-
Wilkens are very close to 1.1 which is the assumed value of RBE.  
We should also note that even though vRBE-Guan is based on only one study, 
Wilkens and Oeflke phenomenological model for RBE calculation with linear α and 
constant β is also a demonstration of the method based on limited data. In addition, 
similar studies were used to make conclusions regarding biologic response of the tissue 
as the ones that justified using a constant RBE. Even in those studies, the RBE of protons 
has an increase towards the end of the range.  
4.2 Sensitivity Analysis 
4.2.1 Sensitivity to αx/βx Fluctuations 
αx/βx is the ratio of tissue parameters for reference radiation, which are photons in 
our case. In vRBE-Wilkens model, this ratio is used when calculating the RBE values. In 
order to observe the behavior of vRBE-Guan compared to vRBE-Wilkens when different 
cell types are used, the αx/βx ratio is increased and decreased by 10%, ( also 20%, 30% for 
patient 1) and the RBE values are calculated based on both variable RBE modes 
respectively. vRBE-Wilkens is observed to be less sensitive to αx/βx changes.  
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Figure 19  Sensitivity of vRBE-Guan to αx/βx ± 0.3 fluctuations – Patient 1. Dotted line demonstrates the upper 0.3, 
and dashed lines show the lower 0.3 limits. 
  
 
Figure 20 Sensitivity of vRBE-Wilkens’ to αx/βx  ± 0.3 fluctuations– Patient 1 .Dashed line demonstrates the upper 
0.3, and dotted lines show the lower 0.3 limits. 
 
RBE weighted dose volume histograms shown noticeable differences in the extent 
of the sensitivities of the two variable RBE models. For every patient, vRBE-Wilkens 
fluctuated less than vRBE-Guan. The underlying reason is related to the formulation of 
the two models. Considering the equation (10), the formula for calculating vRBE-
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Wilkens, we can see that vRBE-Wilkens cannot change much if αx/βx changes because 
the ratio is only multiplied by the inverse of treatment dose, and square of inverse of 
treatment dose. That means this ratio is multiplied by a small number in the equation and 
therefore, the changes in tissue parameters for reference radiation (photons) does not 
cause significant changes to the RBE values. On the other hand, in vRBE-Guan RBE 
calculation formula, equations (13) and (14), since both tissue parameters for reference 
radiation are strongly present and are multiplied by dose and the square of the dose, as 
well as LET, the calculated RBE clearly has a high dependency on the ratio of the tissue 
parameters of both radiations. That means by looking at the equations for both high and 
low LET values, a direct relationship can be noted between reference radiation tissue 
parameters and dose, and proton beam tissue parameters and dose. Thus, the calculated 
RBE values’ sensitivity to tissue parameter fluctuations is significant. This is also true for 
proton beam corresponding tissue parameters. The sensitivity of the RBE functions is 
also shown for the other two patients. Same trend is observed for all three patient cases in 
regard to sensitivity to αx/βx ratio. It is notable that calculated values for “Chiasm” show 
more sensitivity to αx/βx changes for patient 1. This might be caused by the location of the 
tumor volume with regard to Chiasm, but further investigations are anticipated.  
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Figure 21 Sensitivity of vRBE-Guan to αx/βx ± 0.3 fluctuations patient 2. Dotted line demonstrates the upper 0.3, and 
dashed lines show the lower 0.3 limits. 
 
 
 
Figure 22 Sensitivity of vRBE-Wilkens to αx/βx ± 0.3 fluctuations patient 2. Dotted line demonstrates the upper 0.3, 
and dashed lines show the lower 0.3 limits. 
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Figure 23   Sensitivity of vRBE-Guan to αx/βx ± 0.3 fluctuations vRBE-Guan patient 3.   Dotted lines demonstrates the 
upper 0.3, and dashed lines show the lower 0.3 limits. 
 
 
Figure 24    Sensitivity of vRBE-Wilkens’ to αx/βx ± 0.3 fluctuations patient 3. Dotted line demonstrates the upper 0.3, 
and dashed lines show the lower 0.3 limits 
 
The low sensitivity of vRBE-Wilkens to photon beam tissue parameters, can be 
an advantage when compared to vRBE-Guan high sensitivity to tissue parameter values. 
However, as discussed before, the formula of vRBE-Wilkens might not fully reflect the 
dependency of RBE values to tissue parameters. Therefore, the usage of vRBE-Wilkens 
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model should be re-evaluated for precision and accuracy, There might be an argument 
about the benefits of lower sensitivity vs. the extent of the contribution of the parameters 
to calculated RBE values. In addition to comparison of two variable RBE models for 
sensitivity to ± 30% change in αx/βx ratio, vRBE-Wilkens and vRBE-Guan are analyzed 
for the trend of changes if different amount of change occurred. To do so, values for two 
variable RBE models are calculated considering 20%, and 10% increase and decrease in 
αx/βx.  
 
 
Figure 25 Calculated vRBE-Guan values for αx/βx ± 30%, 20%, and 10% for patient 1. 
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Figure 26 Calculated vRBE-Wilkens values for αx/βx ± 30%, 20%, and 10% for patient 1. 
 
A constant and linear trend for vRBE-Guan is observable when 30%, 20%, and 
10% fluctuations in αx/βx are compared. On the other hand the corresponding fluctuations 
of vRBE-Wilkens are observed to be very little but nonlinear to the changes especially 
for PTV.  
4.2.2 Sensitivity of vRBE-Guan to Fit Parameters 
To observe and analyzed the sensitivity of the proposed model to proton beam 
tissue parameters, the fitting values (fit parameters) of α and β of proton are changed by 
0.3 to monitor the behavior of the RBE function. The results and analysis for sensitivity 
are presented in following sections. 
α Fit Parameters 
α parameter of the proton beam demonstrated rather noticeable variability in 
lower LET values, and a nonlinear relationship with LET based on Guan et al 
experiment. Therefore, the fluctuations of α with regard to LET changes are important in 
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the sense of estimating the RBE values especially with expectation of high sensitivity to 
tissue parameters. Another reason to assess the sensitivity of RBE to α parameters is that 
since limited amount of data is available regarding proton biological effectiveness to 
different tissues, the tissue parameters are usually approximated by scaling and/or 
changing the starting point of the fitted function. Such methods for approximating tissue 
parameters include in evitable errors and uncertainties. Therefore, the sensitivity and 
tolerance of the RBE function should be analyzed to observe the effect of such probable 
errors. To monitor the variability of RBE when α changes, the values from fitting the 
tissue parameters are changed by 0.3. 
 
 
Figure 27   Sensitivity of vRBE-Guan to α ± 0.3 Vs. LET fit parameter 0.3 changes – Patient 1. Dotted lines correspond 
to increased alpha parameters, dashed lines show the effect of decreasing the alpha fit parameters, and the 
solid line shows the originally calculated RBE 
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Figure 28   Sensitivity of vRBE-Guan to α ± 0.3 Vs. LET fit parameter 0.3 changes – Patient 1. Dotted lines correspond 
to increased alpha parameters, dashed lines show the effect of decreasing the alpha fit parameters, and the 
solid line shows the originally calculated RBE 
 
 
 
Figure 29   Sensitivity of vRBE-Guan to α ± 0.3 Vs. LET fit parameter 0.3 changes – Patient 3. Dotted lines correspond 
to increased alpha parameters, dashed lines show the effect of decreasing the alpha fit parameters, and the 
solid line shows the originally calculated RBE 
 
 64 
 
The response of the vRBE-Guan to a 30% increase and decrease in α fir 
parameters is demonstrated in Dose Volume Histograms shown in figures 27, 28, and 29. 
vRBE-Guan shows a significant sensitivity toward α fit parameters fluctuations. The 
reason of such sensitivity is the linear and nonlinear relationship of α and LET. LET 
ranges from small values such as 1.5 KeV/µm to significantly higher values. When fit 
parameters for α are changed, the amount of change is multiplied by LET and Dp. 
Therefore the amount of change that is reflected in calculated RBE values are 
significantly high compared to the total absolute value of RBE. As LET increases, the 
deviation of the calculated α based on changed fit values from the original α and 
accordingly the deviation of RBE from its originally calculated values increases. As a 
result, the RBE shows a high level of sensitivity to α fit parameters. Also for Higher 
LETs (LET> 10.8 KeV/µm) the fit parameters contribute to exponential-shaped increase 
of α values. Moreover, a relatively constant rate of change in RBE weighted dose is 
observed when the change of the fit parameter is reduced by 10% and 20%.  
 
Figure 30  Sensitivity of vRBE-Guan to α ± 0.3, 0.2, and 0.1 Vs. LET fit parameter 0.3 changes – Patient 1. Dotted 
lines correspond to increased alpha parameters, dashed lines show the effect of decreasing the alpha fit 
parameters, and the solid line shows the originally calculated RBE values. 
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Sensitivity of vRBE-Guan to β Fit Parameters  
To analyze the RBE model for sensitivity to tissue parameters, α and β should be 
studied.  The sensitivity of vRBE-Guan to β fit parameter changes is of interest since 
although β is multiplied by square of the dose, the β values are relatively small compared 
to α.  
β was observed to have a linear relationship with slow increase rate with LET when LET 
is low, but it nonlinearly increases with regard to LET increase. Below are the cumulative 
RBE weighted dose volume histograms for 30% increase and decrease in β fit 
parameters. 
 
 Figure 31 Sensitivity of vRBE-Guan RBE model to β ± 0.3 Vs. LET fit parameter with 30% changes for patient 1 
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Figure 32 Sensitivity of vRBE-Guan RBE model to β ± 0.3 Vs. LET fit parameter changes for patient 2 
 
 
Figure 33  Sensitivity of vRBE-Guan RBE model to β Vs. LET fit parameter changes for patient 3 
 
Although sensitivity of vRBE-Guan to β is less than its sensitivity to α, the 
amount of measured differences are still significant. On the other hand, as mentioned 
before, this model incorporates the relationship of β for proton beams and LET in 
calculating RBE, while vRBE-Wilkens does not. So vRBE-Guan does have the 
advantage of modeling the β parameter behavior with respect to LET based on an 
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agreeable experimental results, but the level of tolerated sensitivity should be analyzed in 
order to reach a decision whether or not to use such a sensitive approach.  
 
 
Figure 34  Sensitivity of vRBE-Guan to β ± 0.3, 0.2, and 0.1 Vs. LET fit parameter 0.3 changes – Patient 1. Dotted 
lines correspond to increased beta parameters, dashed lines show the effect of decreasing the beta fit 
parameters, and the solid line shows the originally calculated RBE. 
 
The trend of calculated RBE changes when β fit parameters are decreased and 
increased by 30%, 20%, and 10% is also analyzed and demonstrated in figure below. 
Again, a relatively uniform change of variable RBE weighted doses corresponding to fit 
parameter fluctuations is observable. Such fluctuations can be observed to be more 
signified in PTV.   
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Conclusions 
In this chapter two models for calculating relative biological effectiveness are 
analyzed and both are compared to the clinically used constant RBE.  
Three brain tumor cases were selected and patient anatomical information as well as 
clinical treatment plans for those patients were obtained from MD Anderson Cancer 
Center. To compare the three RBE models, RBE and RBE weighted dose for each models 
are calculated. Dose volume histograms are used to measure and illustrate the differences 
between designed scenarios.  
The model of vRBE-Guan yields distinctively higher results than vRBE-Wilkens 
and cRBE and is more sensitive to parameter changes than the other two. However, it 
accounts for the relationship between tissue parameters and LET that are observed to be 
nonlinear based on recent studies, while vRBE-Wilkens considers a linear α, and a 
constant β = βx for proton beams. Therefore, neither can it be stated that vRBE-Wilkens 
is the accurate dependable RBE model to calculate RBE values with, since it is based on 
limited and older experimental data; nor it can be concluded that vRBE-Guan is the 
preferable model because it shows high sensitivity to tissue parameter changes. This is a 
problem since there still is not enough experimental data for proton biological 
effectiveness for various tissues. As a result, for RBE to be calculated based on this 
model, the behavior of tissue vs. LET should be approximated to scale the existing 
function to the parameters of each particular tissue that is under radiation. This scaling 
also should be done for all of the treatment area including organs at risk. Scaling and 
approximating the tissue fit parameters can bring uncertainties and errors into the 
calculations. This means more experiments on proton biological effectiveness can help in 
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reducing the risk of calculating inaccurate RBE values due to inaccurate approximation 
of tissue parameters in RBE formula. 
In regard to continued use of constant RBE, this study found that the proton RBE 
can vary throughout the range and with high dependency to tissue parameters such that 
using 1.1 for proton RBE will underestimate the real value of RBE and therefore, 
underestimate the ability of the beam to damage and kill tumor cells. This is more 
important in regard to sparing the OARs from the damage caused by excess radiation.  
The argument here is that to what extent the sensitivity of the vRBE-Guan can be 
tolerated in order for the variable RBEs to include the response level of particular 
biologic systems to proton beams. Also, this means that the value of considering variable 
biological effectiveness to IMPT planning should be determined to assess the 
justifiability of considering a rather uncertain RBE which in response can model the 
biological response of target tissue against the changes in LET, when it comes to 
unknown tissue parameters. In that sense, robust optimization can be used to take into 
account the uncertainties of this model. Biologically optimized IMPT plans based on 
variable RBE values can be generated to address the effect of variable RBE on treatment 
plans and assess the quality of such plans compared to currently delivered plans based on 
the constant RBE. 
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Future Work 
As mentioned before, biologically optimized IMPT plans based on variable RBE 
evaluated in this study will play an important role in decision making regarding the use of 
variable RBE as opposed to the continued use of constant RBE. Worst case scenarios 
based on RBE model parameters (e.g., slope coefficient in alpha LET dependence and 
beta LET dependence) will be used to compare worst case doses for vRBE-Wilkens and 
vRBE-Guan. Furthermore, three IMPT plans optimized based on cRBE, vRBE-Wilkens 
and vRBE-Guan will be compared by distributions of dose-averaged LET for those three 
plans as the extension of this study.  
A considerable sensitivity to tissue parameter fluctuations was observed in the 
sensitivity analysis section for vRBE-Guan. As a solution to the sensitivities observed for 
the vRBE-Guan, robust optimization can be used to address the high sensitivity of the 
model, so that variable RBE can benefit from the RBE formula as accurate as possible 
based on newly derived experimental data.  
Optimization of IMPT plans based on calculated RBE values for both variable 
RBE models will provide comparative material to evaluate the usage of variable RBE, 
and the effects both RBE models on worst case calculated doses for every patient. 
However, to fully evaluate the implementation of variable RBE, calculated based on 
vRBE-Guan model, information on how the optimized plans influence the treatment 
effectiveness is needed. That means such effect has to be observed with regard to 
treatment outcomes. Less damage to organs at risk is expected to be observed when 
IMPT plans are optimized based on variable RBE values for every patient. Which is 
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rather an important improvement in proton therapy treatment planning especially for 
patients with brain tumor cases with sensitive organs at risk. 
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